Chronic lymphocytic leukemia (CLL) consists of at least two major prognostic subgroups, characterized by different cellular and molecular markers. This observation sparked studies on the function and clinical importance of these markers. In order to address their function adequately, an efficient and reliable method for gene transfer is needed. In this study, we compared efficiency and utility of different gene transfer techniques in CLL. Lenti-, retro-and adenoviral transduction did not yield appreciable numbers of marker gene enhanced green fluorescent protein (EGFP) positive CLL cells, despite various prestimulation protocols. Efficient transgene expression was observed after nucleofection of CLL cells with plasmid DNA, at the expense of low survival rates. After optimization, electroporation of in vitro transcribed mRNA yielded up to 90% EGFP þ CLL cells without affecting survival. Transgene expression remained detectable for at least 2 weeks after electroporation. Furthermore, we could demonstrate overexpression of ZAP70 and of a ZAP70-EGFP fusion protein after electroporation with ZAP70 or ZAP70-EGFP mRNA. We conclude that mRNA electroporation is a novel and straightforward method for highly efficient gene transfer in CLL. The application of this technique should facilitate functional studies on CLL cells, as well as clinical research.
Introduction
One of the most intriguing features of chronic lymphocytic leukemia (CLL) is its clinical and prognostic heterogeneity: while some patients survive for decades without need for treatment, others die within years after diagnosis, despite aggressive therapy. CLL research has focussed on identifying clinical, cytogenetic and molecular markers, allowing to assess prognosis of patients in an early stage of the disease. The most commonly used prognostic markers include lymphocyte doubling time, 1,2 the presence or absence of certain genetic aberrations, 3, 4 the mutation status of the leukemic immunoglobulin variable heavy chain (IgV H ) genes 5, 6 and the expression level of zeta-associated protein of 70 kDa (ZAP70). 7, 8 The existence of significant prognostic differences between subgroups prompted researchers to investigate the underlying pathogenesis, and the mechanisms which could explain the different cellular behavior with regard to apoptosis, survival and response to therapy.
Gene transfer is an obvious tool to study the role of different proteins and non-coding RNAs in these processes. Unfortunately, circulating CLL cells are quiescent cells, mainly in the G 0 /G 1 phase of the cell cycle, 9 hampering efficient gene transfer by most common techniques. Nevertheless, both viral and nonviral gene transfer methods have been applied in CLL research, mainly in connection with immunotherapy research. Successful adenoviral transduction of CLL cells was achieved, but only when the virus was administered at a very high multiplicity of infection (MOI). [10] [11] [12] [13] Adeno-associated viral vectors were used as an alternative, but appropriate prestimulation of the CLL cells by CD40 ligand (CD40L) expressing feeder cells or IgM crosslinking appeared to be necessary for transgene expression. [14] [15] [16] Viral gene transfer methods suffer from additional drawbacks: the production of vectors is laborious and time-consuming and needs specialized equipment, laboratory costs are elevated due to safety requirements, clinical applications are currently restricted and target cells need to express specific receptors to allow binding and entry of the virus.
Nonviral delivery of plasmid DNA by electroporation overcomes most of these difficulties, but has other limitations: transportation to the nucleus and correct transcriptional regulation are necessary for transgene expression. The Nucleofector technology (Amaxa Biosystems GmbH, Cologne, Germany) facilitates transfer of DNA directly into the cell's nucleus, thus allowing transfection of mitotically inactive cells. 17, 18 However, both techniques can cause increased cell death, due to DNArelated cytotoxicity, 19 as well as to cointroduction of bacterial components (for example, lipopolysaccharide) often found in plasmid preparations. 20 Electroporation of mRNA is a commonly used method to load dendritic cells with tumor-associated antigens, so they can be used as tumor vaccines. This technique yields high numbers of viable, transgene expressing dendritic cells, [21] [22] [23] [24] adult stem cells, mesenchymal cells, phytohemagglutinin-stimulated T-cells 25 and CD40-activated normal B-cells, 26, 27 but, to our knowledge, has not been used for CLL cells.
In this paper, we compare a number of viral and nonviral gene transfer methods, including lenti-, retro-and adenoviral transduction, nucleofection of plasmid DNA and electroporation of in vitro transcribed (IVT) mRNA. The latter method proved to be superior to the others, both with regard to transgene expression levels as with regard to cell viability. We could express both native and enhanced green fluorescent protein (EGFP) fusion proteins of ZAP70 in CLL cells, enabling relevant functional studies. We conclude that electroporation of mRNA is a simple, time-saving, cost-effective and clinically applicable method for highly efficient transient gene transfer in CLL, rendering it a promising and valuable tool for fundamental and clinical research. 
Materials and methods

Cell isolation procedure and culture conditions
Stimulation conditions and viral transductions
Prior to transduction, CLL cells were treated with several stimulating agents, added to the culture medium during 1-7 days. In some experiments, CLL cells were cocultured with adherent cell lines for 2-7 days before transduction.
Production of lenti-and retroviral vectors was previously described. 28, 29 EGFP was used as a reporter gene. Two or more days after transduction, viability and EGFP expression were assessed by flow cytometry. All stimulation conditions and transduction experiments are summarized in Table 1 , more details are included in Supplementary Information file 1.
Nucleofection of plasmid DNA
Four different plasmids were used in nucleofection experiments: pmax-GFP (Amaxa Biosystems), pSUPER-EGFP 30 (kindly provided by R Agami, The Netherlands Cancer Institute, Amsterdam, Netherlands), pCMVscript-DNGFR and SIN-LZRS-CMV-DNGFR. Construction of SIN-LZRS-CMV-DNGFR and pCMVscript-DNGFR, both containing a truncated form of nerve growth factor receptor (DNGFR) as a reporter gene, is described in Supplementary Information file 1. Plasmids were propagated in Escherichia coli strain Dh5a and extracted and purified using NucleoBond PC 500 kit (Macherey-Nagel, Düren, Germany) according to the manufacturer's instructions. For endotoxin-free (EF) plasmid preparations, NucleoBond PC 500 EF kit (Macherey-Nagel) was used.
Before nucleofection, CLL cells (1.5 Â 10 6 -4 Â 10 6 ) were pelleted and resuspended in 100 ml Nucleofector Cell Line V Solution (Amaxa Biosystems); 2 mg of plasmid DNA was added and nucleofection was performed by selecting the appropriate program (U07, U13, U15, U16, U23 or T27) of the Nucleofector device (Amaxa Biosystems). After nucleofection, cells were immediately transferred to prewarmed culture medium. Viability and transgene expression were assessed by flow cytometry 24, 48 and 72 or 120 h post nucleofection.
In vitro transcription of mRNA
Two new plasmids (pGEM4Z-ZAP70-A64bis and pGEM4Z-ZAP70-EGFP-A64bis) were derived from pGEM4Z-EGFPA64bis, the latter a modification of the pGEM4Z-EGFP-A64 vector (kindly provided by E Gilboa, University of Miami, Miami, FL, USA). Construction of these vectors is described in Supplementary Information file 1.
All pGEM4Z-derived plasmids were used as templates for in vitro transcription of mRNA as previously described. 31 In brief, linear plasmid DNA was obtained after restriction with SpeI (New England Biolabs, Ipswich, MA, USA) and purified using a QiaQuick PCR Purification Kit (Qiagen, Hilden, Germany). IVT 5 0 capped mRNA was generated with the T7 mMESSAGE mMACHINE kit (Ambion, Austin, TX, USA). After DNase treatment, mRNA was precipitated with LiCl and reconstituted in nuclease-free water (Ambion). RNA concentration was assayed by spectrophotometrical analysis at OD 260 . RNA was stored at À70 1C. 
Electroporation of IVT mRNA
Initially, electroporation was carried out on 0.5 Â 10 6 cells in 75 ml siPORT electroporation buffer (Ambion), with 0.1 cm cuvettes (Eurogentec, Herstal, Belgium) at 130 V and 125 mF. In final experiments, freshly isolated CLL cells were washed twice with IMDM, once with Optimix Washing Solution (Equibio, Ashford, UK) and resuspended in 200 ml Optimix electroporation buffer (Equibio). IVT mRNA was added to the samples, which were transferred to 0.4 cm cuvettes (Eurogentec). Different cell concentrations and amounts of EGFP mRNA were used to optimize the electroporation protocol (see Resultssection). Electroporation was performed with a GenePulserII electroporation instrument (BioRad, Hercules, CA, USA). Optimal electroporation settings were 500 V and 150 mF. After electroporation, cells were immediately transferred to prewarmed culture medium. All experiments included positive controls (electroporated with a fluorescein isothiocyanate (FITC)-conjugated dsRNA oligonucleotide (Block-It Fluorescent Oligo, Invitrogen) and mock controls (electroporated without RNA). At different time points, viability and EGFP or ZAP70 expression of an aliquot of the cells were analyzed by flow cytometry.
Cryopreservation of CLL cells
In some experiments, CLL cells were slowly frozen to À80 1C before or after electroporation in fetal calf serum containing 10% dimethylsulfoxide (Serva, Heidelberg, Germany). After 24 h the cryotubes were transferred to liquid nitrogen. Thawing was performed at 37 1C, and cold IMDM was added dropwise. Cells were pelleted in a precooled (4 1C) centrifuge and resuspended in prewarmed (37 1C) complete IMDM.
Flow cytometric analyses
CLL cells were stained with CD19-phycoerythrin (PE) or CD19-allophycocyanin (APC) antibodies, Jurkat cells with CD3-PE or CD3-APC antibodies (all from BD Biosciences, Erembodegem, Belgium). CLL samples nucleofected with DNGFR-plasmids were also stained with anti-NGFR-PE (Chromaprobe, Maryland Heights, MO, USA). After 30 min, cells were washed, propidium iodide (PI) was added, and samples were analyzed with a FACSCalibur flow cytometer (BD Biosciences). Viability was determined by the percentage of PI-negative, CD19 þ cells; efficiency was defined as the percentage of EGFP þ or NGFR þ cells within the viable cell population. Apoptotic cell death was determined with the Annexin V-PE Apoptosis Detection Kit I (BD Biosciences), according to the manufacturer's instructions. Flow cytometric determination of ZAP70 expression was performed as previously described. 32 Expression levels of EGFP and ZAP70 were determined by mean fluorescence intensity ratios (MFIRs), being the ratio of the mean fluorescence intensity (MFI) of mRNA electroporated samples and mock electroporated samples.
Western blotting
One day after electroporation, CLL cells were lysed in Laemmli sample buffer. Protein lysates were run on a NuPAGE 4-12% Bis-Tris polyacrylamide gel (Invitrogen) and blotted onto a polyvinyldifluoride (PVDF) membrane (Invitrogen). Primary monoclonal antibodies used were mouse anti-actin (clone C4, ICN, Aurora, OH, USA) and mouse anti-ZAP70 (clone 2F3
Statistical analysis
Mean values and standard deviations were calculated with Excel software (Microsoft, Redmond, WA, USA).
Results
Inefficient transduction of CLL cells, despite different stimulation protocols
We first attempted to transduce CLL cells with retro-, lenti-and adenoviral vectors (for an overview of experiments, see Table 1 ). None of the different stimulation and transduction protocols used was able to generate appreciable numbers of viable EGFP þ CLL cells (Table 1) . In most experiments, less than 1% of the viable cells were EGFP þ 48 h after transduction, in contrast to 67% (±27%) (mean % (±standard deviation)) of transduced Jurkat cells. In some conditions (stimulation with DSP30, PMA þ IL-2 or TNFa þ IL-2) more than 50% of viable CLL cells showed green fluorescence, but this shift was also observed in nontransduced control cells, probably due to increased autofluorescence. 
Nucleofection of plasmid DNA causes increased cell death
To increase gene transfer efficiency, we turned to physical transfer methods. Lipofection of plasmids did not yield increased gene transfer compared to transduction (data not shown). Therefore, nucleofection was considered as an alternative. Six different nucleofection programs were tested with pmax-GFP in two independent experiments. Both survival and gene transfer efficiencies were highly variable (Supplementary Figure 1a-b) . On average, program U13 gave the best result: 12% (±13%) of the cells were PI-negative and EGFP þ 24 h after nucleofection (Supplementary Figure 1c) .
Low overall efficiencies were mainly due to low survival rates. This was probably caused by the cytotoxic effect of plasmid preparations, since survival was higher in mock nucleofected cells. However, EF plasmid preparations did not improve survival post nucleofection (data not shown).
The promoter regulating the expression of the transgene also affected efficiency. EGFP expression after nucleofection with pSUPER-EGFP (reporter gene under control of the phosphoglycerate kinase (PGK) promoter) was observed in less than 1% of the viable cell population, whereas up to 64% of living cells were EGFP þ after nucleofection with pmax-GFP and up to 16% efficiency was reached with the DNGFR-plasmids (both reporter genes under control of the cytomegalovirus (CMV) promoter).
Optimization of electroporation conditions of IVT mRNA in CLL cells
We have previously shown that electroporation of mRNA is a less cytotoxic method to transfer genetic material, compared to DNA transfection. 24 However, in initial experiments, only 20% of CLL cells survived electroporation using siPORT buffer (Ambion) (data not shown), which was comparable to survival rates obtained with nucleofection. The use of Optimix electroporation buffer (Equibio) dramatically improved recovery after electroporation, with survival rates up to 90%.
Different amounts (5-10-20-40 mg) of IVT EGFP mRNA were electroporated at 300 V into CLL cells, but no significant difference in survival or percentage EGFP þ cells was observed. However, the intensity of the EGFP fluorescence increased with increasing mRNA quantity: MFIR was 2.9 and 10.3 for cells electroporated with 5 mg mRNA and 40 mg mRNA, respectively.
Cell number did not significantly influence survival (81±3% for 5-10-20 Â 10 6 cells), although survival was lower (64%) when only one million cells were electroporated at 300 V (data not shown).
Initial electrical settings (300 V, 150 mF) were adopted from Van den Bosch et al. 27 who successfully electroporated normal CD40-activated B-cells. Increasing the voltage of the electroporation pulse appeared critical in order to obtain higher percentages of EGFP expressing CLL cells. Efficiency increased from 5 to 91% of EGFP þ cells within the viable cell population when the voltage was raised from 300 to 500 V (Figure 1 ). The MFIR also increased from 3.8 to 122.3 ( Figure 1) . Survival, however, was similar for all samples (69±6%), so by electroporating 10 Â 10 6 CLL cells with 20 mg EGFP mRNA at 500 V, up to 6.6 Â 10 6 living EFGP þ cells could be obtained. EGFP expression was detectable for at least 2 weeks after electroporation, when still 89% of living CLL cells were clearly EGFP þ (Figure 2a) . Survival (Figure 2b ) evolved as in mock electroporated and nonelectroporated control samples (51±3% after 1 week, 13 ± 6% after 2 weeks). This led to a decrease of the overall percentage of viable EGFP þ cells with time, from 66% at 24 h after electroporation to 5% 2 weeks later (Figure 2c) . Furthermore, the intensity of EGFP expression also weakened in time (Figure 2d) .
We further investigated the effect of electroporation on cell survival by Annexin V and 7-amino-actinomycin D (7-AAD) staining. One day after electroporation, viability, defined by the percentage of CD19 þ Annexin V 7-AAD double negative cells, was 60% ( ± 5%), 62% ( ± 12%) and 43% ( ± 16%) for mock electroporated cells, EGFP mRNA electroporated cells and nonelectroporated cells, respectively. On the other hand, survival defined by the percentage of CD19 þ PI-cells, was 69 ( ± 0.4%), 72 ( ± 3%) and 63% ( ± 6%) for the same samples. These results implicate that by using PI-staining, we overestimated cell survival by about 10%, corresponding to Annexin V positive, 7-AAD negative cells. However, since the percentage of apoptotic cells (CD19 þ Annexin V positive and 7-AAD negative), was similar in all samples (20% (±7%), 19% (±9%) and 25% ( ± 11%), respectively), this is not an indication that electroporation would increase apoptosis. In order to assess the effects of cryopreservation of CLL cells before or after electroporation, three different samples were analyzed: noncryopreserved cells, cells cryopreserved before electroporation and cells frozen 2 h after electroporation. Both survival (71, 83 and 71%, respectively) and efficiency (89, 75 and 92% EGFP þ cells, respectively) were similar for all samples.
Overexpression of ZAP70 by electroporation of mRNA
To demonstrate the applicability of our technique in experimental studies, we introduced mRNA encoding native ZAP70 and a ZAP70-EGFP fusion protein in CLL cells. CLL cells were electroporated at 500 V with 10 mg EGFP mRNA, 40 mg ZAP70 mRNA or 40 mg ZAP70-EGFP mRNA. One day after electroporation, survival was 69 ( ± 10%), 62 ( ± 14%) and 64% (±3%), respectively, which was comparable to the viability of cultured cells (47 ± 28%) and mock electroporated cells (68±7%). ZAP70 expression clearly increased in ZAP70 mRNA electroporated cells, compared to untreated or mock electroporated cells. This was demonstrated by flow cytometry (Figure 3 ) and confirmed by western blot (Figure 4a ). The observed difference in ZAP70 expression persisted for at least 3 days (data not shown). Moreover, as expected in samples electroporated with mRNA encoding the ZAP70-EGFP fusion protein, cells with increased ZAP70 expression also showed a higher green fluorescence (Figure 3) . Furthermore, western blot analysis revealed the presence of the ZAP70-EGFP fusion protein, with a predicted molecular weight of 97 kDa (Figure 4b ), while the ZAP70 protein level was similar to that observed in mock electroporated cells (Figure 4a) . [36] [37] [38] [39] In this study, we investigated the applicability of three different gene transfer methods in CLL research. We have demonstrated the superiority of mRNA electroporation to viral transduction and nucleofection of plasmid DNA. We could not realize clear and unequivocal EGFP expression in CLL cells using lenti-, retro-or adenoviral vectors, despite various prestimulation protocols. Nucleofection allowed for efficient transgene expression (up to 64%), but results were highly variable, and viability decreased significantly after nucleofection, leading to a maximum overall efficiency of 21%. Since we observed no effect of EF plasmid preparations, this increased cell death was probably caused by the plasmid DNA itself, 19 rather than by bacterial endotoxins remaining in the plasmid preparations. 20 The use of an appropriate promoter regulating transgene expression appeared critical, since nucleofection with a PGK-EGFP plasmid did not result in EGFP þ cells, whereas nucleofection with a CMV-EGFP construct yielded efficient transgene expression.
After optimization, both survival (up to 80%) and transgene expression (up to 90%) were significantly improved using electroporation of IVT mRNA for transfer of genetic material into CLL cells. Moreover, EGFP expression remained stable for at least 2 weeks after electroporation. Several factors contribute to these results. First of all, Optimix electroporation buffer mimics the natural cytoplasmic environment and contains compounds that decrease cytoplasmic leakage, hence facilitating rapid resealing of the pores and improving recovery. 41 Second, mRNA is used instead of (plasmid) DNA, so appropriate promoter activity is not required. Since transcription already occurred in vitro, nuclear import is not needed, and only translation is necessary for effective transgene expression. Moreover, mRNA appeared less cytotoxic than plasmid DNA preparations. Finally, the resting nature of CLL cells could be an advantage for transient gene transfer methods, because no dilution of the transferred mRNA, nor of the transgenically expressed protein due to cell divisions occurs. This could explain the relatively stable transgene expression levels we observed, although the intrinsic stability of the EGFP protein should also be taken into account.
Cryopreservation before or after electroporation did not affect survival or transgene expression, making it possible to use frozen cells for electroporation experiments or to store electroporated cells in liquid nitrogen until further experiments are carried out.
We further demonstrated that clinically significant genes such as ZAP70 could be efficiently overexpressed in CLL cells by electroporation of mRNA. The use of a ZAP70-EGFP fusion protein made it possible to detect ZAP70 overexpression by simply measuring green fluorescence levels. Although SloanLancaster et al. 42 demonstrated enzymatic and antigenic functionality of the fusion protein in Cos 7 cells, this remains to be confirmed in CLL cells.
It is estimated that the application of mRNA electroporation can be easily extended to other genes related to prognosis or pathogenesis. This methodology is promising as a novel and efficient tool for functional and clinical studies, especially in CLL, but also in other hard to transfect cell types.
